BCAL Diagnostics Future Growth
Future criteria checks 2/6
BCAL Diagnostics is forecast to grow earnings and revenue by 60% and 61.8% per annum respectively while EPS is expected to grow by 66.9% per annum.
Key information
60.0%
Earnings growth rate
66.9%
EPS growth rate
Biotechs earnings growth | 16.0% |
Revenue growth rate | 61.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 22 Feb 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2026 | 12 | 4 | 4 | 4 | 1 |
6/30/2025 | 3 | -7 | -7 | -7 | 1 |
6/30/2024 | 3 | -4 | -3 | -3 | 1 |
12/31/2023 | 4 | -5 | -5 | -4 | N/A |
9/30/2023 | 3 | -5 | -6 | -5 | N/A |
6/30/2023 | 3 | -5 | -6 | -6 | N/A |
3/31/2023 | 2 | -5 | -6 | -5 | N/A |
12/31/2022 | 1 | -5 | -5 | -5 | N/A |
9/30/2022 | 1 | -4 | -4 | -4 | N/A |
6/30/2022 | 1 | -3 | -3 | -3 | N/A |
3/31/2022 | 1 | -3 | -3 | -3 | N/A |
12/31/2021 | 1 | -3 | -3 | -3 | N/A |
9/30/2021 | 0 | -2 | -2 | -2 | N/A |
6/30/2021 | 0 | -2 | -1 | -1 | N/A |
3/31/2021 | 0 | -1 | -1 | -1 | N/A |
12/31/2020 | 1 | 0 | 0 | 0 | N/A |
9/30/2020 | 0 | -1 | 0 | 0 | N/A |
6/30/2020 | 0 | -1 | -1 | -1 | N/A |
6/30/2019 | 0 | 0 | -1 | -1 | N/A |
6/30/2018 | 0 | 0 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BDX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BDX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BDX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BDX's revenue (61.8% per year) is forecast to grow faster than the Australian market (5% per year).
High Growth Revenue: BDX's revenue (61.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BDX's Return on Equity is forecast to be high in 3 years time